This drug is not on the Reformulary. Our Expert Committee did an extensive review of the clinical and cost-effectiveness evidence, and recommended not to fund due to lack of evidence.

CABLIVI is used to treat  
Acquired thrombotic thrombocytopenic purpura (aTTP)